CD107a Marker Partitioning of Mesenchymal Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current autologous stem cell therapies for bone and soft tissue defects face challenges such as suboptimal results in clinical trials, technically demanding procedures, and complications like ischemic failure and donor site morbidity.
Innovation Solution
The use of cell surface CD107a as a marker to differentiate and separate bone-forming and fat-forming progenitor/stem cells within human mesenchymal tissues, allowing for the partitioning of stromal progenitors for improved bone and soft tissue engineering and therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cells are used for bone and soft tissue repair, then treatment potential is improved, but differentiation control and therapeutic precision deteriorate
Solution Approach 1:
The patent segments the heterogeneous mesenchymal stem cell population into distinct subpopulations based on CD107a expression levels (CD107a-high and CD107a-low). This segmentation allows for precise differentiation control where CD107a-low cells are directed toward osteogenic differentiation for bone repair, while CD107a-high cells are directed toward adipogenic differentiation for soft tissue repair, thereby resolving the contradiction between treatment potential and differentiation control
Solution Approach 2:
The patent applies local quality by assigning different functional characteristics to different cell subpopulations within the same mesenchymal stem cell source. CD107a-low cells are enriched for osteogenic potential and used locally for bone defect repair, while CD107a-high cells are enriched for adipogenic potential and used locally for soft tissue repair, achieving precise spatial and functional differentiation control
2Adaptability or versatility
If autologous stem cell procedures are performed, then patient-specific treatment is improved, but procedural complexity and surgical difficulty worsen
Solution Approach 1:
The patent extracts the cell sorting and differentiation enrichment process from the surgical procedure itself, performing CD107a-based FACS sorting and osteogenic/adipogenic differentiation in vitro before implantation. This extraction reduces intraoperative complexity while maintaining patient-specific adaptability, as the cell preparation can be performed in a controlled laboratory setting using standardized protocols
Solution Approach 2:
The patent performs preliminary actions by pre-differentiating mesenchymal stem cells into osteogenic or adipogenic lineages ex vivo based on CD107a expression profiling before surgical implantation. This preliminary differentiation step simplifies the surgical procedure while ensuring patient-specific treatment optimization, as the cells are already primed for their intended function before being implanted
3Adaptability or versatility
If mesenchymal stem cell therapy is applied, then broad tissue repair potential is improved, but therapeutic precision and target specificity worsen
Solution Approach 1:
The patent segments the mesenchymal stem cell population into functionally distinct subpopulations using CD107a expression as the segmentation criterion. CD107a-low cells are specifically targeted for osteogenic differentiation to treat bone defects, while CD107a-high cells are specifically targeted for adipogenic differentiation to treat soft tissue defects, thereby achieving both broad tissue repair potential and precise therapeutic target specificity
Solution Approach 2:
The patent utilizes parameter changes in CD107a expression levels as a biomarker to predict and control differentiation fate. By measuring and sorting based on this specific parameter, the therapy achieves precise targeting of osteogenic or adipogenic outcomes while maintaining the versatility to treat different tissue types based on the initial cell population characteristics
Data Source
AI summary
The present invention has developed methods and compositions utilizing the cell surface CD107a (LAMP-1) as a marker that divides bone-forming and fat-forming progenitor/stem cells within human adipose tissue. The present invention is able to partition stromal progenitors for improved bone and soft tissue engineering and therapies.